Advertisement
Advertisement

Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 2 29 87 63
Fax: +49 (0)711 - 2 29 87 65
send an Email


Archive

Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: Insights from the switching anti-platelet (SWAP) study

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
DOI: http://dx.doi.org/10.1160/TH12-06-0378
Issue: 2013: 109/2 (Feb) pp. 175-360
Pages: 347-355

Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: Insights from the switching anti-platelet (SWAP) study

Online Supplementary Material

See also Editorial by Goto, Tomiya

J. F. Saucedo (1), D. J. Angiolillo (2), R. DeRaad (3), A. L. Frelinger III (4), P. A. Gurbel (5), T. M. Costigan (6), J. A. Jakubowski (6), C. K. Ojeh (6), S. Duvvuru (6), M. B. Effron (6), for the SWAP Investigators

(1) University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; (2) University of Florida College of Medicine - Jacksonville, Jacksonville, Florida, USA; (3) Black Hills Clinical Research Center, Rapid City, South Dakota, USA; (4) Children’s Hospital Boston, Harvard Medical School, Boston, Massachusetts, USA; (5) Sinai Center for Thrombosis Research, Baltimore, Maryland, USA; (6) Eli Lilly and Company or a subsidiary, Indianapolis, Indiana, USA

Keywords

Acute coronary syndrome, clopidogrel, Platelet, prasugrel

Summary

The prevalence of high platelet reactivity (HPR) in patients who have switched from clopidogrel to prasugrel during maintenance phase after an acute coronary syndrome (ACS) event is unknown. Therefore, the effect of switching from clopidogrel to prasugrel on the prevalence of HPR was evaluated. This analysis from the previously reported SWAP (SWitching Anti Platelet) study assessed HPR at baseline, 2 and 24 hours, and seven days after switching from clopidogrel to prasugrel maintenance dose (MD), with or without a prasugrel loading dose (LD) using four definitions: maximum platelet aggregation (MPA) >65% (primary endpoint), MPA >50%, P2Y12 reaction units (PRU) >235, and platelet reactivity index (PRI) ≥ 50%. A total of 95 patients were available for analysis; 56 patients provided DNA for genetic assessments of cytochrome P450 (CYP) 2C19. There were 26 (27.4%) patients with HPR at the end of the clopidogrel run-in (defined as MPA >65%). The HPR prevalence varied by each definition and ranged from 19% (PRU >235) to 68% (PRI ≥ 50 %). A significantly higher HPR prevalence was observed during clopidogrel versus the combined prasugrel therapy groups at seven days as measured by MPA >65% (21.2% vs. 4.5%, p<0.05), PRU >235 (18.8% vs. 0%, p=0.001), and PRI ≥ 50 % (66.7% vs. 7.9%, p<0.0001). There was a significantly higher percentage of subjects carrying at least one reduced function allele with HPR measured by MPA >65% (p=0.02) or PRU >235 (p=0.05) than non-carriers with HPR. Switching ACS patients during maintenance clopidogrel therapy to prasugrel with or without an LD is associated with a reduced HPR prevalence and may provide an alternative strategy to treat patients with HPR, independent of CYP2C19 genotype.

You may also be interested in...

1.
High on-treatment platelet reactivity analysis of the TRIPLET trial

J. G. Diodati (1), J. F. Saucedo (2), T. E. Cardillo (3), J. A. Jakubowski (3), C. Henneges (4), M. B. Effron (3), F. R. Lipkin (5), J. R. Walker (5), S. Duvvuru (3), S. S. Sundseth (6), H. N. Fisher (7), D. J. Angiolillo (8)

Thromb Haemost 2014 112 2: 311-322

http://dx.doi.org/10.1160/TH13-09-0747

2.

Online Supplementary Material

C. B. Olivier (1), P. Diehl (1), K. Schnabel (1), P. Weik (1), Q. Zhou (1), C. Bode (1), M. Moser (1)

Thromb Haemost 2014 111 2: 266-272

http://dx.doi.org/10.1160/TH13-06-0508

3.

Online Supplementary Material

N. Straub (1), A. Beivers (2), E. Lenk (3), D. Aradi (4), D. Sibbing (5)

Thromb Haemost 2014 111 2: 290-299

http://dx.doi.org/10.1160/TH13-08-0679